TG Therapeutics, Inc.: New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous ...

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI rema ...
TMCnet

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

17% of patients treated with BRIUMVI continuously for 6 years achieved Confirmed Disability Improvement (CDI) lasting at least 24 weeks compared to 13.3% of patients who switched from teriflunomide to ...
NewsBytes

Antioxidants: Myth v/s facts

Antioxidants are often touted as the magic bullet for good health, but the truth is, the science behind them is often ...
The Manila Times

PhenQ Australia Over the Counter | Fast Acting Fat Burner and Appetite Suppressant Australian Launch OTC by PhenQ

Widely regarded as arguably the best OTC fat burner and appetite suppressant pill, PhenQ helps users tackle fat loss from ...
eLife

Macroscopic Analyses of RNA-Seq Data to Reveal Chromatin Modifications in Aging and Disease

This valuable study analyzes aging-related chromatin changes through the lens of intra-chromosomal gene correlation length, which is a novel computational metric that captures spatial correlations in ...